Given the company is probably in the best position it has ever been in terms of product maturity, human trials, ongoing R&D and innovative world class COVID respiratory analysis software then I would conclude the company market capitalisation should equally reflect or exceed a higher valuation it achieved in the past two years, IMHO.
On the 17 June 2020, RAP had a peak share price of $0.19. Thus the current $0.115 takeover offer is still 40% below this previous higher share price.
Therefore, I can see higher highs in share price developing in line with further product development maturity and timely global product release.
- Forums
- ASX - By Stock
- RAP
- Ann: Quarterly Activities Report and Appendix 4C
Ann: Quarterly Activities Report and Appendix 4C, page-76
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
RAP (ASX) Chart |
Day chart unavailable